Join Growin Stock Community!

Praxis precision medicines, inc.PRAX.US Overview

US StockHealthcare
(No presentation for PRAX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PRAX AI Insights

PRAX Overall Performance

PRAX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PRAX Recent Performance

-0.21%

Praxis precision medicines, inc.

0.05%

Avg of Sector

-0.31%

S&P500

PRAX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PRAX Key Information

PRAX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PRAX Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Price of PRAX

PRAX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PRAX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-14.34
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
953.14
PB Ratio
27.19
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-3658.53%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-14.34
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
953.14
PB Ratio
27.19
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-3658.53%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PRAX's latest earnings report released?

    The most recent financial report for Praxis precision medicines, inc. (PRAX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PRAX's short-term business performance and financial health. For the latest updates on PRAX's earnings releases, visit this page regularly.

  • How is PRAX's revenue growth?

    In the latest financial report, Praxis precision medicines, inc. (PRAX) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does PRAX have?

    At the end of the period, Praxis precision medicines, inc. (PRAX) held Total Cash and Cash Equivalents of 357.33M, accounting for 0.38 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PRAX's EPS continuing to grow?

    According to the past four quarterly reports, Praxis precision medicines, inc. (PRAX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -3.51. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PRAX?

    Praxis precision medicines, inc. (PRAX)'s Free Cash Flow (FCF) for the period is -76.33M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 36% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of PRAX?

    The latest valuation data shows Praxis precision medicines, inc. (PRAX) has a Price-To-Earnings (PE) ratio of -30.45 and a Price/Earnings-To-Growth (PEG) ratio of -3.92. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.